Andrew B. Singleton, Ph.D.

NIH Distinguished Investigator

Center for Alzheimer's and Related Dementias


Building T44, Room 112
9000 Rockville Pike
Bethesda, MD 20892


Research Topics

Dr. Andrew Singleton has published more than 700 articles on a wide variety of topics. He is the Director of the Center for Alzheimer’s and Related Dementias within the Intramural Research Program, in addition to being Chief of the Molecular Genetics Section within the Laboratory of Neurogenetics. Singleton’s group works on the genetic basis of neurological disorders including Parkinson's disease, Alzheimer’s disease, dystonia, ataxia, dementia with Lewy bodies, and amyotrophic lateral sclerosis (ALS). His team seeks to identify genetic variability that causes or contributes to disease and to use this knowledge to understand the underlying molecular processes. Dr. Singleton’s group discovered a number of genetic mutations that cause disease, including the alpha-synuclein multiplication mutation and mutations in LRRK2. Dr. Singleton was a founding member of the International Parkinson Disease Genomics Consortium, and the Global Parkinson’s Genetics Program. His laboratory has identified the majority of the known genetic risk factors for Parkinson disease.


Dr. Singleton received his B.Sc. from the University of Sunderland, UK and his Ph.D. from the University of Newcastle upon Tyne, UK. His postdoctoral studies were spent at the Mayo Clinic in Jacksonville Florida. Andrew moved to the National Institute on Aging at NIH Bethesda, MD in 2001 and became a principal investigator leading the Molecular Genetics Unit in 2002. In 2007 he became a tenured senior investigator at the National Institute on Aging, in 2008 he was named the Chief of the Laboratory of Neurogenetics, and in 2016 he was honored as an NIH Distinguished Investigator. While still leading the Molecular Genetics Section, in 2021 he stepped down as the Chief of the Laboratory of Neurogenetics and became the Director of the Center for Alzheimer's and Related Dementias.

Dr. Singleton currently serves on the scientific advisory board of the Lewy Body Dementia Association; he is a member of the editorial boards of Neurodegenerative Diseases, Neurogenetics, Movement Disorders, (Associate Editor), Lancet Neurology, the Journal of Parkinson's Disease, NPJ Parkinson's Disease (Associate Editor), and the Journal of Huntington's Disease. Dr. Singleton was awarded the Boehringer Mannheim Research Award in 2005, the NIH Director's Award in 2008 and again in 2016, and the Annemarie Opprecht Award for Parkinson's disease research in 2008. In 2012 Dr. Singleton became the first person to win the Jay van Andel Award for Outstanding Achievement in Parkinson's Disease Research. In 2017 he was awarded the American Academy of Neurology Movement Disorders Award and an Honorary Doctorate from his alma mater, the University of Sunderland.

Selected Publications

  1. Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, Tan M, Kia DA, Noyce AJ, Xue A, Bras J, Young E, von Coelln R, Simón-Sánchez J, Schulte C, Sharma M, Krohn L, Pihlstrøm L, Siitonen A, Iwaki H, Leonard H, Faghri F, Gibbs JR, Hernandez DG, Scholz SW, Botia JA, Martinez M, Corvol JC, Lesage S, Jankovic J, Shulman LM, Sutherland M, Tienari P, Majamaa K, Toft M, Andreassen OA, Bangale T, Brice A, Yang J, Gan-Or Z, Gasser T, Heutink P, Shulman JM, Wood NW, Hinds DA, Hardy JA, Morris HR, Gratten J, Visscher PM, Graham RR, Singleton AB, 23andMe Research Team., System Genomics of Parkinson's Disease Consortium., International Parkinson's Disease Genomics Consortium.. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18(12):1091-1102.
  2. Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C, Stefansson H, Liu X, Pliner H, Lee JH, Cheng R, International Parkinson's Disease Genomics Consortium (IPDGC)., Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI)., 23andMe., GenePD., NeuroGenetics Research Consortium (NGRC)., Hussman Institute of Human Genomics (HIHG)., Ashkenazi Jewish Dataset Investigator., Cohorts for Health and Aging Research in Genetic Epidemiology (CHARGE)., North American Brain Expression Consortium (NABEC)., United Kingdom Brain Expression Consortium (UKBEC)., Greek Parkinson's Disease Consortium., Alzheimer Genetic Analysis Group., Ikram MA, Ioannidis JP, Hadjigeorgiou GM, Bis JC, Martinez M, Perlmutter JS, Goate A, Marder K, Fiske B, Sutherland M, Xiromerisiou G, Myers RH, Clark LN, Stefansson K, Hardy JA, Heutink P, Chen H, Wood NW, Houlden H, Payami H, Brice A, Scott WK, Gasser T, Bertram L, Eriksson N, Foroud T, Singleton AB. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet. 2014;46(9):989-93.
  3. Hernandez DG, Nalls MA, Gibbs JR, Arepalli S, van der Brug M, Chong S, Moore M, Longo DL, Cookson MR, Traynor BJ, Singleton AB. Distinct DNA methylation changes highly correlated with chronological age in the human brain. Hum Mol Genet. 2011;20(6):1164-72.
  4. Singleton A, Hardy J. The Evolution of Genetics: Alzheimer's and Parkinson's Diseases. Neuron. 2016;90(6):1154-1163.
  5. Chang D, Nalls MA, Hallgrímsdóttir IB, Hunkapiller J, van der Brug M, Cai F, International Parkinson's Disease Genomics Consortium., 23andMe Research Team., Kerchner GA, Ayalon G, Bingol B, Sheng M, Hinds D, Behrens TW, Singleton AB, Bhangale TR, Graham RR. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. Nat Genet. 2017;49(10):1511-1516.

Related Scientific Focus Areas

This page was last updated on Wednesday, July 20, 2022